STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percent [185/192]) were not receiving corticosteroids.1 Among the 174 patients receiving STELARA as their first biologic for UC (biologic-naïve), 71.8 percent (125) of these patients were in symptomatic remissionb after 44 weeks of maintenance, and 67.2 percent (117) were in remission at week 200. A separate presentation of UNIFI LTE study data showed the majority (79.1 percent) of STELARA randomized patients who received corticosteroids at maintenance baseline and were treated with STELARA in the LTE were able to eliminate the use of corticosteroids by week 200.2 These data are being presented at the United European Gastroenterology (UEG) Week 2022 congress taking place in-person in Vienna and virtually from October 8-11.1,2“The final LTE results of the UNIFI study demonstrated that STELARA can be an effective long-term treatment option for patients living wit...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Allergy | Allergy & Immunology | Arthritis | Babies | Babies Heart Conditions | Back Pain | Bleeding | Brain | Brain Cancers | Breast Needle Aspiration | Breastfed | Bronchitis | Canada Health | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Child Development | Children | Chronic Pain | Colectomy | Colon Cancer | Colorectal Cancer | Complementary Medicine | Corticosteroid Therapy | Cough | ENT & OMF | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Grants | Headache | Health Management | Heart | Herbs | Hospitals | Hypertension | Infectious Diseases | Inflammatory Bowel Disease | Learning | Legislation | Marketing | Migraine | Milk | National Institutes of Health (NIH) | Neurology | Neuroscience | Nurses | Nursing | Pain | Pharmaceuticals | Politics | Pregnancy | Profits and Losses | Psoriasis | Psoriatic Arthritis | Pulmonary Hypertension | Respiratory Medicine | Rheumatology | Science | Shingles | Shingles (Herpes Zoster) Vaccine | Skin | Skin Cancer | Sore Throat | Stelara | Study | Training | Tuberculosis | Tuberculosis (BCG) Vaccine | Ulcerative Colitis | Universities & Medical Training | Urinary Tract Infections | USA Health | Vaccines | Vitamins | Weight Loss